July 19-21 2016 Boston, USA Book now and save up to $700 4 th Annual Improve Preclinical Predictability & Translational Success to Enhance Clinical Trial Results for the Next Generation of Targeted Cancer Therapies 27 Expert Speakers Include: Uri Herzberg Senior Director, Preclinical & Translational Development Celgene Cellular Therapeutics Jianguo Ma Associate Director, Translational In Vivo Pharmacology EMD Serono Eric Murphy Global Scientific Director, Translational Oncology Crown Bioscience Natalia Malkova Principal Research Investigator, Pharmacology Sanofi Excellent Tumor Models meeting that was very well attended. Great program, speakers and panelists, which made for productive discussions, networking and exchange of ideas. Genentech Jason Fleming Professor Department of Surgical Oncology MD Anderson Cancer Center LEAD PARTNER PROGRAM PARTNERS www.tumor-models.com #Tumor_Models Tumor Models RESEARCHED & DEVELOPED BY:
Benefits of Attending Are Your Preclinical Models Delivering Accurate Clinical Predictions? Update Your knowledge of the Oncology Field and Adapt Your Preclinical Strategies to Enhance Clinical Success The 4th Annual Tumor Models Boston is back with even more preclinical and clinical case studies. Achieve rapid clinical and regulatory success by enhancing your preclinical predictability studies, biomarker validation, imaging capabilities and translational decision-making. Harness the very latest data from more predictable and physiologically-relevant preclinical models to better inform the design and interpretation of first-in-man trials for targeted patient populations. Join us at Tumor Models Boston to witness large pharma, biotech and leading academia demonstrate how to apply more predictable oncology models to improve translation of preclinical outcomes and highlight novel in vitro, in vivo, and in silico modeling techniques that are laying the foundations of clinical success. With the immunotherapy race well and truly on, alongside a hot pursuit to find the most synergistic combination therapies, scrutinize humanized, syngeneic and patient-derived xenograft models to enhance their use and effectively translate preclinical knowledge into clinical utility. Improve the validation and understanding of your drug candidates by incorporating superior imaging approaches with your preclinical modeling strategy. As the most established and trusted conference dedicated to preclinical oncology, Tumor Models Boston is a unique opportunity to optimize your preclinical and translational best practice, equipping you with the tools and knowledge to rapidly advance your most promising candidates. Top 5 Key Takeaways to Implement: Top 5 Case Studies to Discover: Learn how the industry are adapting preclinical 1 strategies for biologics to mediate the clinical 1 progression of immunotherapies Discover how to evaluate preclinical models to 2 optimize efficacy and PK/PD predictions for 2 combination therapies Harness the latest developments in in vivo 3 imaging protocols to optimize translational 3 research decision making Understand the role of cancer stem cells in 4 4 disease progression through novel 3D models encapsulating the tumor microenvironment in vitro Adopt physiologically relevant in vitro and in 5 5 vivo models incorporating metastatic disease Discover how Sanofi, Celgene and OncoMed are developing and utilizing humanized mice to analyze the action of immunotherapies in a immune microenvironment Learn how Janssen are developing cancer immunotherapies through imaging tools to detect and characterize immune cell infiltrate Harness the preclinical combination therapy strategies GSK, Dicerna Pharma and MedImmune are applying to progress multiple agent therapies into the clinic Learn from Pfizer and EMD Serono to evaluate how accurately the PDX preclinical data translated into the early clinical outcomes Explore how AbbVie are harnessing in silico modeling to aid the discovery and clinical development of immunotherapies and combination therapies
Expert Speakers Faculty Uri Herzberg Senior Director, Preclinical & Translational Development Celgene Cellular Therapeutics Jianguo Ma Associate Director, Translational In Vivo Pharmacology EMD Serono Eric Murphy Global Scientific Director, Translational Oncology Crown Bioscience Edward Rosfjord Senior Principal Scientist, In Vivo Pharmacology Pfizer Arijit Chakravarty Director, Modeling & Simulation (DMPK) Takeda Natalia Malkova Principal Research Investigator, Pharmacology Sanofi Neal Goodwin VP, Corporate Research Development Champions Oncology Oliver Ghobrial Senior Scientist III, Translational Modeling and Simulation (TMS) AbbVie Peter King Principle Scientist, Molecular Imaging Janssen Research & Development Shanthi Ganesh Associate Director, Preclinical Oncology Dicerna Pharmaceuticals Deb Knoerzer Vice President Research Operations Horizon Discovery Shu-Hui Liu Director, Department of Tumor Biology Rinat R&D Rick Huntress Director, Business Development The Jackson Laboratory Christopher Murriel Senior Scientist II, OncoMed Pharmaceuticals Jason Fleming Professor, Department of Surgical Oncology MD Anderson Cancer Center Jonathan Rios-Doria Scientist II MedImmune Hon Leong Director, St. Joseph s Hospital, Assistant Professor, Departments of Surgery Western University Jenni Bernoulli R&D Director Pharmatest Services Matthew Lowerison Medical Biophysics Ph.D. Candidate, University of Western Ontario, in collaboration with Visualsonics Fujifilm Bryan Spring Assistant Professor of Physics Northeastern University Esmaiel Jabbari Professor, Chemical Engineering, Biomedical & Chemical Engineering University of South Carolina Vinagolu Rajasekhar Senior Research Scientist Memorial Sloan Kettering Cancer Center Rachel Gerstein Associate Professor University of Massachusetts Medical School Lorcan Sherry Chief Scientific Officer Oracle Bio Qunsheng Ji VP, Head of Oncology Business Unit WuXi AppTec Maryland Franklin Vice President, Scientific Development MI Bioresearch Margarida Bernardo Research Scientist Wayne State University
Pre-Conference Workshops, Tuesday July 19th 2016 Workshop A Establishing Routine Humanized Mice Models for the Development of Cancer Immunotherapies Date: Tuesday July 19th 2016 Time: 8.30am-11.30am What are the current methodologies the industry are utilizing to develop humanized mice models in house? Sapna Yadavilli Manager, Translational Research, Immuno-Oncology GSK To highlight the current hurdles preventing accurate efficacy and PK/PD readouts from humanized mice To overcome inconsistency between models in order to harness humanized mice models for routine preclinical practice What developments are on the horizon to advance in vivo models with humanized immune systems for the progression of cancer immunotherapies? Workshop B Developing QSP Strategies to Optimize Translational Decision Making To Advance Cancer Immunotherapies Date: Tuesday July 19th 2016 Time: 12pm-3pm Enhance PK/PD predictions to drive your most promising candidates to first in human trials by advancing existing QSP strategies Oliver Ghobrial Senior Scientist III Translational Modeling & Simulation (TMS), AbbVie Learn through existing case studies on how to design the preclinical trials to incorporate both in vivo responses and in silico modeling Discover how to utilize QSP to develop and to predict responses to novel combination therapies Workshop C Enhancing the Translational Success of Combination Therapies Through Advanced Preclinical Modeling Date: Tuesday July 19th 2016 Time: 3.30pm-6.30pm Outline where the field is in terms of combination therapies- What platforms are being utilized to predict combinations in the clinic What are the key challenges (technical/strategic) that are preventing the development of combination therapies (specific to small molecules, biologics, chemo agents)? How is the field addressing these hurdles- Practical takeaways for clinical trial design, dosing schedule How to design clinical trials specifically for combination therapies involving cancer immunotherapies Arijit Chakravarty Director, Modeling & Simulation (DMPK) Takeda Very enjoyable and informative meeting. The workshops at the beginning were something new to me and I found them a very useful means of idea sharing and networking. Boehringer Ingelheim
Conference Day One, Wednesday July 20 th 2016 8.00 Registration & Breakfast 9.00 Chair s Opening Remarks Optimizing Immuno-Competent Models to Accelerate Immunotherapy Development 9.10 The Global Immuno-Oncology Platform: Preclinical Immuno-Competent Models for Translational Research Comparison of immunocompetent mouse models for immunotherapy PD/ efficacy studies Examples of targeted therapy/immunotherapy combinations, vaccines, CAR-T cell therapy, and other approaches to condition the tumor microenvironment Overview of the Translational Oncology platform including mouse PDX trials, 3D ex vivo screening, murine syngeneic PD screening, GEMM allografts, and new knock-in mice with chimeric human/mouse targets for immuno-oncology 9.40 Discover the Advances in Preclinical In Vivo Models Harnessed for the Development of Immunotherapies Addressing which models are providing highly predictive preclinical data including efficacy, PK/PD in the development of immunotherapies What s on the horizon to improve the models to enhance translational success 10.10 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors 10.40 Morning Refreshments & Speed Networking Eric Murphy, Global Scientific Director, Translational Oncology, Crown Bioscience Uri Herzberg, Senior Director, Preclinical & Translational Development, Celgene Cellular Therapeutics Rick Huntress, Director of Business Development, Clinical & In Vivo Services, The Jackson Laboratory Track A - Preclinical Models for Enhanced Predictability and Clinical Translation of Targeted Therapies and Biologics 11.40 Is Translation Always the Answer? Phase I Design Challenges for Immunotherapies and ADCs What evidence counts towards validation of a preclinical model, and why does it matter? What are the design choices for Phase I? How can we address them using validated preclinical models? What if the preclinical models we have aren t validated? Arijit Chakravarty, Director, Modeling & Simulation (DMPK), Takeda 12.10 Pimasertib Preclinical-Phase II-like Trial (PP2T) Result from Patient-Derived Xenograft Models Correlated to Clinical Outcomes Test MEK inhibitor, Pimasertib in PDX models in different indications using pre-clinic phase II-like trial (PP2T) platform Compared PP2T result with clinic Phase I/II results of Pimasertib Preclinical result could predict clinical outcomes Jianguo Ma, Associate Director, Translational In Vivo Pharmacology, EMD Serono Track B - Preclinical Modeling for Cancer Immunotherapies 11.40 Antitumor Activity of Isatuximab (SAR650984, Anti-CD38 mab) in a Preclinical Humanized Mouse Model Antitumor activity of Isatuximab in immunodeficient mouse models Immuno-modulatory properties of Isatuximab Effect of Isatuximab on the immune microenvironment of solid tumor in a humanized mouse model Natalia Malkova, Principal Research Investigator Pharmacology, Sanofi 12.10 The Use of Humanized Mice and Patient-Derived Xenografts Tumor Models in Preclinical Immuno-Oncology Drug Development Learn about the current advances in harnessing PDX models to develop humanized mice Discuss strategies for utilizing these models for routine use in the preclinical development of cancer immunotherapies Christopher Murriel, Senior Scientist II, OncoMed Pharmaceuticals
12.40 Utilization of Advanced Preclinical Tools in Immuno-Oncology Models Utilization of 14-color flow cytometry to evaluate the immune phenotype Utilization of radiation in syngeneic tumor models and the potential for immuno-oncology Maryland Franklin, Vice President, Scientific Development, MI Bioresearch 12.50 Networking Lunch Preclinical Models For Enhanced Predictability and Clinical Translation of Targeted Therapies and Biologics 14.30 Harnessing PDX Models to Evaluate Standard-of-Care Treatment in the Clinic Standard-of-care treatment from the perspective of response rates in the clinic and response rates in PDX Evaluating response of PDX to standard-of-care treatment to validate this hypothesis and to identify dosages and schedules that can be used to identify sensitive and resistant PDX models useful for developing combination strategies for new therapies, since many therapies will be incorporated in combination with standard-of-care regimens in the clinic Edward Rosfjord, Senior Principal Scientist, In Vivo Pharmacology, Pfizer 15.00 Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal solid tumor that is often refractory to the limited systemic treatment options that are currently available Results from patient-derived xenograft (PDX) based animal experiments often parallel clinical outcomes, and anecdotal reports suggest PDX models can guide clinical treatment Translation of the PDX model into a method suitable for practical personalized cancer treatment is prevented by the intense resources and time resources necessary to generate and test each tumorgraft We describe a method to overcome this limitation. We have developed a unique ex vivo live tissue sensitivity assay (LTSA) that allows each PDX derived from a PDAC tumor to be maintained in a 96-well plate and screened against clinically relevant regimens within 3-5 days Jason Fleming, Professor Department of Surgical Oncology, MD Anderson Cancer Center 12.40 Interpreting the Impact of Therapeutic Response on Immune Cell Proximity and Spatial Distribution within the Tumor Microenvironment Utilizing IHC and multiplex IF analysis for quantifying cell types within the tumor microenvironment Generating spatial and proximity measures on a range of tumor / microenvironment markers to investigate and drive clinical hypotheses forward with respect to effects of Inflammation and Immunotherapies Lorcan Sherry, Chief Scientific Officer, Oracle Bio Preclinical Models Targeting the Tumor Microenvironment for Enhanced Predictability Chair: Margarida Bernardo, Research Scientist, Wayne State University 14.30 Advancing our Understanding of Cancer Stem Cells through Physiologically Relevant Preclinical Modeling Why, to date, have none of the conventional animal models of human cancers delivered on our goals for their cure? How does live cancer tissue banking as PDXs of a conceptual mouse hospital our understanding of original parent tumor heterogeneity, its origin, and its functional microenvironment What are the prospects of PDXs in discovery and development of CSC biomarkers, patient-specific therapeutics and co-clinical trials under newly emerging immuno-oncology landscape Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center 15.00 Role of Macrophages in Nanoparticle- Mediated Drug Targeting to Cancer Stem Cells Cancer recurrence and resistance is related to the existence of a very small population of initiating cells or stem cells (CSCs) in the tumor tissue with high expression of ATP-binding cassette (ABC) transporter proteins associated with drug resistance One approach to overcome carrier-mediated drug resistance in CSCs is to use nanoparticles (NPs) for drug encapsulation and intracellular delivery by endocytosis To highlight the effect of macrophages on toxicity of Paclitaxel conjugated to polyhedral oligosilsesquioxane (POSS) NPs toward breast CSCs in a novel 3D culture system will be presented Esmaiel Jabbari, Professor, Chemical Engineering, Biomedical & Chemical Engineering, University of South Carolina
15.30 Afternoon Refreshments & Poster Session With an agenda packed with case studies and data-driven presentations, the Tumor Models poster session will allow you deeper access into the most innovative research. Meet the scientists conducting exciting research and pick their brains to gain insights into the emerging oncology models. Apply their learnings straight into your own work, cultivate research collaborations and leave inspired by new ideas. 16.30 Tumor Models Interactive Breakout Roundtable Session In this 1 hour session, you will have the opportunity to choose from four different topics and catch up on the latest advancements and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following: 1. 2. 3. 4. Developing predictive humanized mice- What are the current limitations? How can we use preclinical models to optimize the predictability of novel combination therapies? What platforms are available for advancing biomarker discovery, on the molecular and genome level? What added benefits can organoid cultures bring to preclinical studies? Esmaiel Jabbari, Professor, Chemical Engineering, Biomedical & Chemical Engineering, University of South Carolina Margarida Bernardo, Research Scientist, Wayne State University 18.00 Chair s Closing Remarks 18.05 Close of Day 1 18.10 Drinks Reception Hosted by Crown Bioscience Networking at Tumor Models Boston 2016 Speed Networking A structured networking session - run like speed dating- especially designed to facilitate quick introductions to the majority of attendees within the preclinical oncology field. Use the time wisely to meet new contacts, reconnect with old friends and identify those you want to spend more time with. Round Table Discussions Take part in facilitated discussion sessions focused around specific, high priority issues surrounding preclinical models. Discuss your experiences and observations within focus groups then share your and the other groups findings with the main conference. Structured Networking Breaks In between the formal presentations the networking carries on. Use the multiple refreshment and lunch breaks to continue your discussions in an informal relaxed atmosphere. Move from scientific discoveries into meaningful collaborations.
Conference Day Two, Thursday July 21 st 2016 8.00 Breakfast & Networking 9.00 Chair s Opening Remarks Developing Personalized Combination Therapies to Target the Heterogenetic Patient Population 9.10 Model Selection for Targeted Therapies in Oncology Drug Development Harnessing Case studies of using PDX models for efficacy testing and companion diagnostics development Model selection and establishment for chemo, ADC, antibody and IO combination therapies What future model developments are required? 9.40 Advanced PDX Tumor Biology Platforms for Drug Advancement Large collections of PDX models allow for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms and biomarker signatures of response Robust systems of myeloid engraftment, including hematopoietic stem cells for immune system modeling and AML engraftment for high throughput multipatient in vivo screens, now provide for expanded PDX screening with a wider scope of therapeutic agents Coupled-PDX trials are being advanced where clinical trials are combined with companion PDX studies to help guide follow-on trial design Matched patient-pdx-directed trials will see PDX models used to screen for experimental drug efficacy, with patients enrolled onto trials based on their PDX drug response Shu-Hui Liu, Director, Department of Tumor Biology, Rinat R&D/Pfizer Neal Goodwin, VP, Corporate Research Development, Champions Oncology 10.10 Combining Immunotherapy with Chemotherapy: Lessons from Mouse Models Demonstrate potent combination efficacy between chemotherapy and immunotherapy in vivo Describe models used and key considerations for experimental design Model responses and predictability of combination efficacy Jonathan Rios-Doria, Scientist II, MedImmune 10.40 Highly Characterized Patient-derived Xenograft Collections for Preclinical Studies Use of highly characterized PDX models allow efficient preclinical drug screening Ex vivo proliferation studies using PDX models mirrors in vivo studies Deb Knoerzer, Vice President Research Operations, Horizon Discovery 11.10 Morning Refreshments & Networking Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues Sanofi Aventis
Track A - Development of Preclinical Models with Advanced Incorporation of Metastatic Disease Chair: Esmaiel Jabbar, Professor, Chemical Engineering, Biomedical & Chemical Engineering, University of South Carolina 11.50 Mouse Models of Advanced Metastatic Disease: Development, Challenges and Utility with a Key Role for In Vivo Molecular Imaging To describe a xenograft mouse model of metastatic ovarian cancer (peritoneal carcinomatosis), developed by gynecologic oncologists in Prof. Tayyaba Hasan s laboratory at Massachusetts General Hospital, that recapitulates the disease pattern in humans To address challenges that include heterogenous metastasis seeding and growth rates that result in poor reproducibility How to apply in vivo molecular imaging using miniature optical endoscopy to improve reproducibility by directly visualizing tumor growth and tracking responses to experimental therapies in time A hybrid targeted therapy and molecular imaging platform with sufficient resolution, contrast and selectivity for disseminated cancer micrometastases will be described that was successfully developed using this model To discuss early ideas for improving upon this model and the imaging technology to better model and tackle tumor heterogeneity Bryan Spring, Assistant Professor of Physics, Northeastern University 12.20 Why and How to Test Drug Efficacy in Mouse Models of Bone Metastasis? Clinical significance of bone metastases Significance of bone microenvironment on tumor dormancy and growth How to test drug efficacy on bone metastases in preclinical studies Jenni Bernoulli, R&D Director, Pharmatest Services 12.35 Modeling Drug Combinations Containing an RNAi Nanoparticle in Preclinical Models of CRC Inhibition of both Wnt signaling and MAPK signaling using an RNAi drug targeting beta-catenin and a small molecule inhibitor of MEK, respectively Comparison of primary and metastatic CRC using subcutaneous and orthotopic cell-line derived xenografts Shanthi Ganesh, Associate Director, Preclinical Oncology, Dicerna Pharmaceuticals Track B - Translation Success Through Optimized Imaging in Predictive In Vivo Models 11.50 Use of High Frequency Ultrasound Imaging to Quantify Drug Responses in Patient Derived Xenografts of Renal Cell Carcinoma The assessment patient-specific drug resistance to anti-angiogenic agents using the promising application of the chicken chorioallantoic membrane (CAM) patient-derived xenograft model To demonstrate that tumors implanted in the CAM of chick embryos grown ex ovo can be productively imaged using high-frequency ultrasound and quantitative measures of tumor volume, blood volume, blood velocity, and blood flow can be obtained To quantify responses to anti-angiogenic therapy within a clinically relevant time window, providing actionable data to inform therapy selection Since anti-angiogenic agents are the primary therapy for Renal Cell Carcinoma, this procedure could be useful for patient-specific drug sensitivity evaluation, enabling selection of individualized treatments prior to initiating systemic therapy Matthew Lowerison, Ph.D. Candidate, University of Western Ontario, Imaging Research Laboratories, Robarts Research Institute, in collaboration with Visualsonics Fujifilm 12.00 Developing Imaging Tools to Detect Immune Cell Infiltration to Enhance Translation of Immunotherapies The use of imaging in preclinical studies to advance our understanding of immunotherapies in humanized mouse models Lessons learnt and still learning to enhance the use of imaging in the development of cancer immunotherapies Peter King, Principle Scientist, Molecular Imaging, Janssen Research & Development 12.30 Modulation of Tumor Progression by Immune Check Point Inhibitors (Anti-PD-1/ CTLA-4) in Murine Tumor Models Establishing predictive models that are clinically relevant How have these models enhanced preclinical predictions for efficacy, pharmacology and toxicology Better understand the potential impact of immune system when developing therapeutic agents Charles River- Speaker to be confirmed
13.05 Networking lunch Harness Novel Models to Advance Personalized Medicine Approaches 14.20 PDXovo: Ultrafast Prediction of Drug Sensitivities Prior to Treatment via Intratumoral Multiregional Analysis Outline the development of a high-throughput, ultrafast, patient derived xenograft (PDX) model using the chorioallantoic membrane (CAM) of chick embryos to evaluate treatment strategies for patients with metastatic RCC Pairing this model with high-frequency ultrasound imaging to quantify tumor volume, vascularity, and perfusion, and thereby evaluate drug efficacy This PDX model, in conjunction with high-frequency contrast-enhanced ultrasound, permits functional tumor heterogeneity studies to be completed within two weeks- making this an approach that could guide the selection of drugs, anticipate resistance to targeted therapies, and predict patient outcomes in a clinically-relevant time window This a cost-effective model and enables the investigator to confidently perform high-throughput PDX experiments with tumor heterogeneity in mind 14.50 Understanding MoA of Immune Checkpoint Inhibitors in Preclinical Models Use checkpoint inhibitors to dissect mode of actions from phonotype to genetic profiling of TCR and tumors Modulate tumor responsiveness by combination therapies Explore biomarkers in syngeneic tumor models and cancer patients 15.00 Quantitative Systems Pharmacology (QSP): Strategy and Applications in Immunotherapy Discovery and Clinical Development A Quantitative Systems Pharmacology (QSP) in silico model was developed to describe the homeostatic interactions between the tissue parenchyma and the immune system in different individual phenotypes A novel approach to virtual patient and virtual population development will be presented Utility of this approach to evaluate combination therapies for optimal effect will be demonstrated 15.30 Patient-Derived Xenografts of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine Development of a new experimental paradigm: Mouse Avatars of lymphoma progression using NSG mice Description of three examples of B cell lymphoma derived from patient samples that were successfully engrafted into NSG mice, which includes a spectrum of B-cell lymphoma subtypes including FL, transformed DLBCL, and high grade BL (with MYC translocation) This experimental approach provides a powerful platform for evaluating response to standard and novel therapeutic approaches. This model will also permit investigation of the basis for bone marrow and CNS dissemination of tumor cells in the NSG mouse model, given the clinical importance of B cell lymphoma invasion of these sites Hon Leong, Director of the Translational Prostate Cancer Research Laboratory St. Joseph s Hospital, Assistant Professor, Departments of Surgery, Western University Qunsheng Ji, VP, Head of Oncology Business Unit, WuXi AppTec Oliver Ghobrial, Senior Scientist III, Translational Modeling & Simulation (TMS), AbbVie Rachel Gerstein, Associate Professor, University of Massachusetts Medical School 16.00 Chairman s Closing Remarks 16.05 Close of Tumor Models Boston 2016 Excellent conference, very good balance of presentation between suppliers, academics, large pharma and biotech. The quality of talks was good and the informal networking was very useful. Preclinical Project Manager at e-therapeutics plc
Sponsors Lead Partner Program Partner Crown Bioscience Crown Bioscience provides Translational Platforms focused on fast-tracking candidates to identify biomarkers and patient responders based on the pharmacological response of human surrogate models. Power your Drug Discovery using the world s largest commercial collection of well-characterised PDX in passage (HuPrime) plus a curated, searchable database of patient, genotypic and phenotypic data as well as pharmacological response (HuBase). Identify potential biomarkers (HuSignature ) based on pharmacological response or use your biomarker signature to identify models available for screening to confirm patient responder and non-responder populations (HuTrials ). Fast forward your drug discovery programs today. www.crownbio.com Champions Oncology Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft offers an enhanced xenograft mouse avatar model for growing and testing human tumors. Champions Personalized TumorGrafts empower patients and physicians using an in vivo xenograft mouse avatar based diagnostic model that has shown to be predictive of a patients clinical response to cancer treatments and anticancer therapies. www.championsoncology.com Program Partner Program Partner Horizon Discovery Horizon Discovery combines long scientific heritage in translational research with GENESIS, a precision gene editing platform incorporating raav, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organisations. www.horizondiscovery.com The Jackson Laboratory The Jackson Laboratory is an independent, nonprofit biomedical research institution and a National Cancer Institute-designated Cancer Center. Founded in 1929, the Laboratory applies its eight decades of expertise in genetics to increase understanding of human disease, advancing treatments and cures for cancer, neurological and immune disorders, diabetes, aging and heart disease. It models and interprets genomic complexity, integrates basic research with clinical application, educates current and future scientists, and empowers the global biomedical community by providing critical data, tools and services. www.jax.org OracleBio OracleBio provides high precision digital image analysis services for detailed quantification of protein and RNA within cells and tissues to support Oncology R&D and diagnostics development. Using state of the art Definiens image analysis software, we deliver accurate and consistent quantification of histological, IHC and ISH marker staining on a cell-by cell basis. We have extensive experience of tumor xenograft analysis, covering a wide range of drug response read-outs including viable and necrotic content, mechanistic markers (proliferation, microvessel density, apoptosis, DNA damage etc) and specific biomarker expression within sub-cellular compartments (nucleus, cytoplasm and membrane). www.oraclebio.com MI Bioresearch (formerly Molecular Imaging) Molecular Imaging, Inc. (MII) is a premier preclinical oncology CRO (Contract Research Organization) with outstanding expertise and one of the broadest, most relevant ranges of models and services in the industry. We offer an unparalleled array of cutting-edge technologies to meet the demands of the rapidly changing field, including a world-class immuno-oncology services program. www.molecularimaging.com
Pharmatest Pharmatest Services Ltd is a CRO offering preclinical efficacy services for the pharmaceutical industry. We offer both in vitro and in vivo models in the fields of oncology and skeletal diseases. In oncology we have special expertise in clinically predictive orthotopic and metastasis models, and especially models of bone metastasis. www.pharmatest.com Charles River Charles River provides preclinical discovery services with specific experience in cancer pharmacology and specialty oncology models. Our broad range of models and support services allow clients to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates. www.criver.com WuXi AppTec WuXi AppTec is a leading global pharmaceutical, biopharmaceutical and medical device R&D company with operations in China and US. www.wuxiapptec.com Translational Drug Development (TD2) Translational Drug Development (TD2) is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible. The focus is on cutting edge science into translational solutions for our partners. Driven by science and motivated by patients, TD2 strives to make a significant impact on cancer. Roundtable Leader Cellaria Biosciences Cellaria develops oncology models that fully represent the diversity, individuality, and complexity of cancer. Our models enable investigators and innovators to gain actionable insights for the development of the next generation of personalized oncology therapeutics. Cellaria is based in Cambridge, MA. Become a Commercial Partner Contact Diane McKenna Commercial Director Tel: +44 (0)203 141 8700 Email: sponsor@hansonwade.com VisualSonics VisualSonics is the world s leading developer of highresolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company s enabling technology allows researchers at the world s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, and developmental biology areas. The technology supports applications that include genetic research, phenotypic studies and drug development. www.visualsonics.com Envigo Envigo is an international CRO offering a comprehensive range of development services to pharmaceutical and biopharmaceutical companies. We help our customers develop safe and effective new compounds. Our Research Models and Services operating group provides high-quality research models and lab animal diets with support services worldwide. www.envigo.com Exhibitor Indica Labs Indica Labs is the first company to offer tissue specific and application specific image analysis algorithms in a truly integrated digital pathology environment. Pharmaceutical, healthcare, and research organizations worldwide utilize Indica tools for high-throughput, wholeslide image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology, and more. www.indicalab.com
Pricing & Venue Venue The Colonnade Hotel One 120 Huntington Ave, Boston, MA, 02116, USA Accommodation: Overnight accommodation is not included in the registration fee. Pricing Industry Register & Pay before Friday May 20th 2016 Register & Pay before Friday June 17th 2016 Standard Prices PLATINUM PACKAGE: Conference + 3 Workshops $4096 (Save $700) $4296 (Save $500) $4398 (Save $400) GOLD PACKAGE: Conference + 2 Workshops $3497 (Save $600) $3697 (Save $400) $3797 (Save $300) SILVER PACKAGE: Conference + 1 Workshop $2898 (Save $500) $3098 (Save $300) $3198 (Save $200) BRONZE PACKAGE: Conference Only $2299 (Save $400) $2499 (Save $200) $2699 Workshops (each) $699 Academic Register & Pay before Friday May 20th 2016 Register & Pay before Friday June 17th 2016 Standard Prices PLATINUM PACKAGE: Conference + 3 Workshops $2596 (Save $500) $2697 (Save $400) $2797 (Save $300) GOLD PACKAGE: Conference + 2 Workshops $2197 (Save $400) $2297 (Save $300) $2397 (Save $200) SILVER PACKAGE: Conference + 1 Workshop $1798 (Save $300) $1898 (Save $200) $1998 (Save $100) BRONZE PACKAGE: Conference Only $1399 (Save $200) $1499 (Save $100) $1599 Workshops (each) $699 Register Team Discounts * www.tumor-models.com/register Tel: +1 212 531 5898 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU Terms & Conditions Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. 10% discount 3 delegates 15% discount 4 delegates 20% discount 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time and that discounts are not applicable to academic pricing. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH * All discount offers (including team discounts) require payment at the time of registration to receive any discount. Early Bird discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Code: 5793